CTOs on the Move

Neos Therapeutics

www.neostx.com

 
Neos Therapeutics is focused on developing, manufacturing and commercializing branded products utilizing our proprietary extended-release drug delivery technology platform, which serves as the basis for our three product candidates being investigated for the treatment of attention deficit hyperactivity disorder (ADHD). Our ADHD product candidates include the following formulations; oral disintegrating tablets (ODT) and liquid suspension. Drug Delivery Platform: Our proprietary extended-release drug delivery platform has enabled us to create new patient- and caregiver-friendly dosage forms of methylphenidate and amphetamine. Formulations: In 2014 alone, 63.1 million prescriptions for medications with ADHD labeling, and principally in extended-release formulations, were written in the United States. ...
  • Number of Employees: 100-250
  • Annual Revenue: $50-100 Million
  • www.neostx.com
  • 2940 N. Hwy 360 Suite 400
    Grand Prairie, TX USA 75050
  • Phone: 972.408.1300

Executives

Name Title Contact Details

Funding

Neos Therapeutics raised $76.28M on 05/17/2016

Similar Companies

Pack Line

Pack Line Corp. is a Cleveland, OH-based company in the Manufacturing sector.

Capron Manufacturing

Capron Manufacturing is a Capron, IL-based company in the Manufacturing sector.

Kirkwood Holding

Kirkwood Holding is a Cleveland, OH-based company in the Manufacturing sector.

Electra-Gear

Electra-Gear Corp. is a Union Grove, WI-based company in the Manufacturing sector.

Digital Diagnostics

Digital Diagnostics is a pioneering AI diagnostics company on a mission to transform the quality, accessibility and affordability of healthcare. Founded and led by Dr. Michael Abramoff, an ophthalmologist, neuroscientist and computer engineer, Digital Diagnostics developed a patented biomarker-based approach to build autonomous algorithms that make clinical decisions without human intervention. Digital Diagnostics and its flagship product IDx-DR, an autonomous AI system FDA-authorized to diagnose diabetic retinopathy and diabetic macular edema, has proven that intelligent diagnostic platforms can be used safely, efficiently and equitably to improve patient outcomes. As it expands into other diagnostic capabilities, Digital Diagnostics has paved the way for automated diagnosis to become a new standard of care that will contribute significantly to democratizing healthcare.